Eli Lilly And Company · NYSE:LLY
Eli Lilly And — J.P. Morgan Healthcare Conference (January 2026)
9 slides from Eli Lilly And's conference presentation, January 2026
Slide 1: Not for promotional use
Not for promotional use
Slide 2: Safe Harbor Provision and Other Information
Safe Harbor Provision and Other Information This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the
Slide 3: Entering NEW ERA in treating people with obesity and related complications
Entering NEW ERA in treating people with obesity and related complications FROM TO Broad portfolio of medicines across Portfolio Single marketed product expanded indications PORTFOLIO Globally launched and widely available, with Supply Demand outpacing supply 13 sites under construction SUPPLY ACCES
Slide 4: Expanding focus to help even more patients
Expanding focus to help even more patients BROAD PIPELINE POTENTIAL TO HELP 1B PEOPLE Launch & Late Phase Programs Obesity Diabetes TIRZEPATIDE ORFORGLIPRON Obstructive Pain ELORALINTIDE RETATRUTIDE Sleep Apnea BRENIPATIDE Cardiovascular Renal 6 Hepatic Others Additional Clinical Stage Programs 34 D
Slide 5: Investing $55B to create sustainable advantage
Investing $55B to create sustainable advantage 13 sites under construction globally, with additional site forthcoming Lebanon, Lebanon, Huntsville, Carolina, Houston, Research Triangle Park, Concord, Indiana (1) Indiana (2) Alabama Puerto Rico Texas North Carolina North Carolina Indianapolis, Katwij
Slide 6: Advancing science across all therapeutic areas
Advancing science across all therapeutic areas PURSUING DISEASES WITH NEW MEDICINES TO DRIVE FUTURE GROWTH SIGNIFICANT UNMET NEEDS Launch & Late Phase Programs # Patients1 IMLUNESTRANT OLOMORASIB Elevated lipoprotein(a) 63M TERSOLISIB PIRTOBRUTINIB (PI3Kα) SOFETABART VEPUGRATINIB MIPITECAN (FRα) Chr
Slide 7: Speeding innovation to patients
Speeding innovation to patients DIFFERENTIATED NEW PLATFORMS ACQUIRING DEVELOPMENT TO ADDRESS PROMISING ENGINE UNMET NEED SCIENCE 3.5 years faster Antibody Drug Conjugates 39 transactions vs industry from discovery in 2025 including: to first launch1 Radioligand Therapies siRNA 24 NME launches $4 bi
Slide 8: Innovating beyond the molecule
Innovating beyond the molecule Lilly AI-Powered Catalyze 360 Drug Discovery LillyDirect Supported 180+ biotech Collaboration with NVIDIA Served 1 million+ patients in 2025 companies since 2023 Building industry’s most powerful supercomputer Not for promotional use 8
Slide 9: Trademarks
Trademarks All trademarks and trade names referred to in this presentation are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this presentation, the property of their respective owners. Solely for convenience, the trademarks an
Eli Lilly and Company — J.P. Morgan Healthcare Conference (January 2026) on 6ix